User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists

Postgraduate Medicine

Volumn 127, Issue 8, 2015, Pages 818-826

  Shaefer, Charles F ^a   Kushner, Pamela ^b   Aguilar, Richard ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Kushner Wellness Center   (United States)

^c Diabetes Nation LLC   (United States)

Author keywords

Glucagon like peptide 1; Glucagons; Insulin; Receptor agonist; Type 2 diabetes mellitus

Indexed keywords

ALBIGLUTIDE; ANOREXIGENIC AGENT; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; SEMAGLUTIDE; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INCRETIN; METFORMIN;

ARTICLE; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG USE; ENERGY EXPENDITURE; FOOD INTAKE; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; IMMUNOGENICITY; INJECTION SITE REACTION; INSULIN RELEASE; KIDNEY FAILURE; META ANALYSIS (TOPIC); NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PANCREAS ISLET BETA CELL; PANCREATITIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; STOMACH EMPTYING; TACHYCARDIA; THYROID CANCER; WEIGHT REDUCTION; AGONISTS; CALORIC INTAKE; COMBINATION DRUG THERAPY; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MEDICATION COMPLIANCE; METABOLISM; PANCREAS; PRIMARY HEALTH CARE;

BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ENERGY INTAKE; GASTRIC EMPTYING; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MEDICATION ADHERENCE; METFORMIN; PANCREAS; PRIMARY HEALTH CARE; WEIGHT LOSS;

EID: 84964033566     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2015.1090295     Document Type: Article

References (64)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA, USA: Department of Health and Human Services; 2014.
2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–9.
3. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract 2015;21:438–47.
4. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract 2015;21:1–87.
5. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076–82.
6. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131–57.
7. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986;63:492–8.
8. Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011;34:S251–7.
9. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773–95.
10. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002;45:1111–19.
11. Hojberg PV, Vilsboll T, Rabol R, Knop FK, Bache M, Krarup T, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009;52:199–207.
12. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallelgroup study. Lancet 2002;359:824–30.
13. Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinck JW, Bierman EL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976;42:222–9.
14. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidylpeptidase IV as a treatment for type 2 diabetes. Diabetes 1998;47: 1663–70.
15. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402–5.
16. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77–88.
17. Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 2006;7:367–74.
18. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24:2943–52.
19. Williams DL. Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. Endocrinology 2009;150:2997–3001.
20. Beiroa D, Imbernon M, Gallego R, Senra A, Herranz D, Villarroya F, et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes 2014;63:3346–58.
21. Heppner KM, Marks S, Holland J, Ottaway N, Smiley D, Dimarchi R, et al. Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice. Diabetologia 2015;58:2124–32.
22. Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinkmann BH, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 2002;282:G424–31.
23. Owens DR, Monnier L, Bolli GB. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. Diabetes Metab 2013;39: 485–96.
24. TRULICITY (dulaglutide) injection, for subcutaneous use. US prescribing information. Indianapolis, IN: Eli Lilly and Company; 2015.
25. TANZEUM (albiglutide) for injection, for subcutaneous use. US prescribing information. Research Triangle Park, NC: Glaxo- SmithKline LLC; 2015.
26. BYETTA (exenatide) injection. US prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals, LP; 2015.
27. VICTOZA (liraglutide [rDNA origin] injection). US prescribing information. Plainsboro, NJ: Novo Nordisk Inc; 2015.
28. BYDUREON (exenatide extended-release for injectable suspension). US prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2015.
29. Jimenez-Solem E, Rasmussen MH, Christensen M, Knop FK. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr Opin Mol Ther 2010;12:790–7.
30. Kapitza C, Lynge J, During M, Jensen C. Safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD) of single escalating doses of semaglutide, a unique once weekly GLP-1 analogue, in healthy male subjects. Diabetologia 2012;55:S341.
31. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, et al. Use of twice-daily exenatide in basal insulintreated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103–12.
32. Rosenstock J, Fonseca VA, Gross JL, Ratner RE, Ahren B, Chow FC, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care 2014;37:2317–25.
33. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 2011;34: S279–84.
34. Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255–61.
35. Aroda VR, Henry RR, Han J, Huang W, DeYoung MB, Darsow T, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012;34:1247–58 e22.
36. Abdul-Ghani MA, Williams K, Kanat M, Altuntas Y, DeFronzo RA. Insulin vs GLP-1 analogues in poorly controlled type 2 diabetic subjects on oral therapy: a meta-analysis. J Endocrinol Invest 2013;36:168–73.
37. Tibaldi JM. Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes. Adv Ther 2014;31:289–317.
38. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259–67.
39. Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes 2013;6:453–67.
40. Diamant M, Van Gaal L, Guerci B, Stranks S, Han J, Malloy J, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol 2014;2:464–73.
41. Wysham CH, MacConell LA, Maggs DG, Zhou M, Griffin PS, Trautmann ME. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial. Mayo Clin Proc 2015;90:356–65.
42. Bogelund M, Vilsboll T, Faber J, Henriksen JE, Gjesing RP, Lammert M. Patient preferences for diabetes management among people with type 2 diabetes in Denmark - a discrete choice experiment. Curr Med Res Opin 2011;27:2175–83.
43. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275–86.
44. Apovian CM, Bergenstal RM, Cuddihy RM, Qu Y, Lenox S, Lewis MS, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 2010;123: 468 e9–17.
45. Holst JJ. Incretin hormones and the satiation signal. Int J Obes (Lond) 2013;37:1161–8.
46. Saxenda (liraglutide [rDNA origin] injection). US prescribing information. Plainsboro, NJ: Novo Nordisk Inc; 2015.
47. Brice KR, Tzefos MK. The clinical efficacy and safety of glucagon-like peptide-1 (GLP-1) agonists in adults with type 2 diabetes mellitus. Clin Med Insights Endocrinol Diabetes 2011;4:13–24.
48. Girman CJ, Kou TD, Cai B, Alexander CM, O’Neill EA, Williams-Herman DE, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 2010;12:766–71.
49. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150–6.
50. Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014;348:g2366.
51. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Glucagon-like peptide-1 receptor agonists and pancreatitis: a metaanalysis of randomized clinical trials. Diabetes Res Clin Pract 2014;103:269–75.
52. Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, et al. Pancreatic safety of incretin-based drugs– FDA and EMA assessment. N Engl J Med 2014;370:794–7.
53. Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473–86.
54. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab 2013;15:737–49.
55. Lorber D. GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Ther 2013;31:238–49.
56. Avogaro A, Vigili de Kreutzenberg S, Fadini GP. Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy. Curr Diab Rep 2014;14:483.
57. Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 2013;166:823–30 e5.
58. Steinberg WM, Nauck MA, Zinman B, Daniels GH, Bergenstal RM, Mann JF, et al. LEADER 3–lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. Pancreas 2014;43:1223–31.
59. Daniels GH, Hegedus L, Marso SP, Nauck MA, Zinman B, Bergenstal RM, et al. LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial: preliminary observations. Diabetes Obes Metab 2015;17:477–86.
60. Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, et al. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a longterm cardiovascular end point trial of lixisenatide versus placebo. Am Heart J 2015;169:631–8 e7.
61. Aguilar RB. Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success. Clin Ther 2011;33:408–24.
62. Koro CE, Chhabra P, Stender M, Spain CV, Allen JK, Krzywy HJ. Treatment utilization patterns of GLP-1 agonists and DPP-4 inhibitors among type 2 diabetics in a U.S. commercially insured population: 2005–2011. Diabetes 2013;62:A415.
63. Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 2014;37:2763–73.
64. Buse JB, Peters A, Russell-Jones D, Furber S, Donsmark M, Han J, et al. Is insulin the most effective injectable antihyperglycaemic therapy? Diabetes Obes Metab 2015;17:145–51.